

Akebia Therapeutics, Inc. 245 First Street, Suite 1100 Cambridge, MA 02142

T: +1 617.871.2098 F: +1 617.871.2099 www.akebia.com

January 6, 2017

VIA EDGAR

Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-4628

Attention: Mr. Jim B. Rosenberg

Mr. Rolf Sundwall Ms. Keira Nakada

Re: SEC Comment Letter dated December 22, 2016

Akebia Therapeutics, Inc.

Form 10-K for the Fiscal Year Ended December 31, 2015

Filed March 14, 2016

Form 10-Q for the Quarterly Period Ended September 30, 2016

Filed November 9, 2016 File No. 001-36352

Dear Mr. Rosenberg, Mr. Sundwall, and Ms. Nakada:

This letter is to confirm our telephone conversation on January 6, 2017, with Mr. Sundwall of the staff of the Securities and Exchange Commission regarding our request for an extension of time to respond to your comment letter dated December 22, 2016. As discussed, we require additional time to prepare a response. As a result, we expect to submit our response by January 20, 2017. We extend our thanks for allowing this extension.

Please contact Paul Kinsella of Ropes & Gray LLP at 617-951-7921 if you have any questions. We appreciate your accommodation in this matter.

Very truly yours,

/s/ Jason Amello

Jason Amello

Senior Vice President, Chief Financial Officer and Treasurer